Loading clinical trials...
Loading clinical trials...
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
Conditions
Interventions
PLX3397
vemurafenib
Locations
6
United States
UCLA
Los Angeles, California, United States
University of Colorado, Denver
Aurora, Colorado, United States
Vanderbilt University
Nashville, Tennessee, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Institute Gustave Roussy
Paris, France
University Hospital Essen
Essen, Germany
Start Date
November 5, 2013
Primary Completion Date
September 22, 2014
Completion Date
September 22, 2014
Last Updated
May 28, 2020
Lead Sponsor
Daiichi Sankyo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions